Teva (TEVA) Investors Like CEO Succession Plan, Shares Move Higher
Tweet
Share
E-mailGet Alerts TEVA Hot Sheet
Price: $32.03 -0.59%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.1%
Revenue Growth %: -3.6%
Overall Analyst Rating:
SELL (= Flat)
Dividend Yield: 2.1%
Revenue Growth %: -3.6%
Join SI Premium – FREE
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA),shares are trading about 5 percent better Tuesday, following its CEO succession plans.
Late last Friday, Teva said CEO Shlomo Yanai will retire, and Bristol-Myers Squibb's Dr. Jeremy Levin will assume the role in May 2012.
For more color, click here.
Late last Friday, Teva said CEO Shlomo Yanai will retire, and Bristol-Myers Squibb's Dr. Jeremy Levin will assume the role in May 2012.
For more color, click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cadrenal Therapeutics CMO resigns, separation terms disclosed
- Gogo reshuffles executive role in subsidiary reorganization
- Hims & Hers CAO Irene Becklund to depart in October 2026
Create E-mail Alert Related Categories
Insiders' Blog, Management ChangesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
